Defense Production and Active Pharmaceutical Ingredients Act

HR 6895, the Defense Production and Active Pharmaceutical Ingredients Act, amends a provision in the 2023 National Defense Authorization Act. It expands federal research and development funding to include "active pharmaceutical ingredients" and their key starting materials, alongside existing commodity chemicals. This change directly affects manufacturers and researchers working on domestic production of critical drug components. The bill modifies existing defense authorization language to explicitly include these pharmaceutical elements in eligible R&D support.